Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1714/3502.34885 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations of acute kidney injury with oral anticoagulants: a disproportionality analysis of the food and drug administration adverse event reporting system (FAERS) database.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Xi' an Central Hospital, Xi'an, Shaanxi, China.
Objective: The FDA Adverse Event Reporting System (FAERS) was used to evaluate the associations between oral anticoagulants (OACs) and acute kidney injury (AKI).
Methods: Disproportionality analysis were applied to data in the FAERS database from January 2004 to December 2023 to detect adverse events (AEs) for various OACs. The adjusted reporting odds ratios (RORs) calculated using multiple logistic regression were used to explore the risk factors for OACs-associated AKI.
Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in nephrotic syndrome patients: a retrospective study.
Thromb J
January 2025
College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Background: Nephrotic syndrome (NS) is associated with an increased risk of venous thromboembolism (VTE). Anticoagulants are widely used in the prevention of VTE in NS patients. The use of direct oral anticoagulants (DOACs) has not been studied intensively in NS patients.
View Article and Find Full Text PDFEfficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review.
Open Heart
January 2025
The University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada.
Background: Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr. This scoping review aimed to summarise current evidence on the safety and efficacy of anti-thrombotic therapy after MVr, identify knowledge gaps and propose a future study design.
Methods: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Clinicaltrials.
Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population.
Adv Ther
January 2025
Department of Hospital Medicine, Ochsner Health System, New Orleans, LA, 70121, USA.
Introduction: Atrial fibrillation (AF), a common heart rhythm abnormality, is linked to a higher risk of stroke. Traditionally, warfarin has been the primary anticoagulation treatment for reducing the stroke risk. The new standard of treatment by direct oral anticoagulants (DOACs) offers greater benefits including improved efficacy and fewer adverse effects with reduced monitoring.
View Article and Find Full Text PDFLeft atrial appendage occlusion and radiofrequency ablation in a patient with atrial fibrillation and dextrocardia: a case report.
Front Cardiovasc Med
January 2025
Department of Cardiology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Background: Dextrocardia is a rare congenital condition, affecting approximately 1 in 10,000-12,000 individuals. When combined with atrial fibrillation (AF), it becomes even rarer. "One-stop" surgery, including combined radiofrequency ablation (RFA) and left atrial appendage occlusion (LAAO), has become a common clinical treatment for patients with AF who develop cerebral infarction despite regular oral anticoagulants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!